GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) happens to be a biopharmaceutical provider focusing on the discovery, development as well as the commercialization of a wide spectrum of therapeutics from its proprietary cannabinoid product platform.
The company through one of its top executives has come forward to make public American Academy of Neurology (AAN)’s issuance of the positive results associated with a second Phase 3 study (GWPCARE3) of Epidiolex® (cannabidiol or CBD) among adults and children as well who are struggling with Lennox-Gastaut syndrome (LGS).
According to some close sources, the data will most probably be presented during the forthcoming meeting linked with the American Academy of Neurology (AAN) situated in Boston, MA. The announcement from a speculative point of view is sure to put a smile on the faces of the large number of patients struggling with related complications.
As a matter of fact, the Lennox-Gastaut syndrome happens to be one of the trickiest types of epilepsy for medical experts to deal with. It was disclosed from the placebo-controlled research that indeed Epidiolex is observed to clinically provide significant reductions in an acceptable safety and tolerability profile in line with the seizure frequency.
According to one of the provider’s top executives, Epidiolex has the capacity to offer a positive change towards dealing with LGS .On that same note, he moved ahead to show his great excitement following the plans the company had put in place in the future prescriptions.
It goes without saying that what any top company needs to ensure is the setting up of a more standardized as well as a tested pharmaceutical formulation of cannabidiol. That will help a huge deal towards helping patients around the globe.
The trial set up revealed that indeed Epidiolex was from a general perspective well tolerated. However, the recent Phase 3 Study had showcased a pattern of some adverse events that had remained quite persistent over time.
It was a great thing that during a prestigious meeting there was the highlighting of the Phase 3 epilepsy program, and that the wide neurological community needed to pay closer attention as a matter of fact!